3629 results for «726»
3629 results
DCB in diffuse disease and small vessels: LIVE Educational Case from National University Heart Centre - Singapore
10 Oct 2025 – From AICT-AsiaPCR 2025
This educational session focuses on the application of drug-coated balloons (DCB) in the management of diffuse coronary disease and small vessel pathology. It guides clinicians in identifying suitable lesion subsets, optimizing lesion preparation using advanced imaging and physiological assessments, and determining the appropriate timing to transition...
Cracking the tricuspid code "the Bicaval revolution"
16 Nov 2025 – From PCR London Valves 2025
This session decodes the advancement of caval valve therapy with the TricValve system, offering novel solutions for tricuspid regurgitation and right heart failure. It incorporates insights from clinical trials, real-world cases, and guideline integration, detailing imaging techniques and strategies for complex patient management including rescue interventions.
Nightmare in cathlab
10 Oct 2025 – From AICT-AsiaPCR 2025
This session provides comprehensive guidance on managing complications encountered in the catheterization laboratory. It covers practical approaches to a range of procedural complications, strategies to prevent vascular site issues in emergency situations, and essential tips for managing coronary perforations, aneurysms, and complications during vessel preparation. The...
From repair to replacement: a portfolio of options for your mitral and tricuspid regurgitation patients
16 Nov 2025 – From PCR London Valves 2025
This session explores a full spectrum of therapeutic options for mitral and tricuspid regurgitation, focusing on the PASCAL Precision system for targeted repair and the SAPIEN M3 transcatheter mitral valve replacement. Through beating heart simulators, case discussions, and clinical evidence, participants will understand the versatility and...
Day case TAVI - The future standard of care for most TAVI patients
16 Nov 2025 – From PCR London Valves 2025
Examining the UK experience, this session discusses the emerging standard of day case TAVI and its potential application across Europe. It evaluates patient-centered risks and benefits, operational requirements, and the evolving role of clinical valve coordinators to facilitate safe and efficient day case pathways for TAVI...
How to optimise TAVI outcomes in extreme patient anatomies?
16 Nov 2025 – From PCR London Valves 2025
Focused on optimizing TAVI outcomes in patients with challenging anatomies, this session addresses strategies for small and large annular sizes, as well as lifetime management considerations for younger patients. Case presentations and implant strategy discussions provide practical guidance for achieving optimal procedural results in extreme patient...
Coronary interventions: access, devices and outcomes
10 Oct 2025 – From AICT-AsiaPCR 2025
This session delves into the latest developments in coronary interventions, highlighting advances in vascular access techniques, innovative devices, and clinical outcomes. Topics include endothelial progenitor cell dysfunction in restenosis, the efficacy of distal radial artery (DRA) puncture and sheathless catheters in underserved areas, the use of...
NSTEMI, complex ACS and anatomy
10 Oct 2025 – From AICT-AsiaPCR 2025
This session focuses on complex cases involving non-ST elevation myocardial infarction (NSTEMI), acute coronary syndromes (ACS), and challenging coronary anatomy. It presents unique clinical scenarios such as pediatric rescue PCI, management of significant distal lesions with proximal PCI, anatomical variations complicating interventions, mixed cardiovascular disease management,...
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
